Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Total Liabilities
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has total liabilities worth $2.99 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Liminatus Pharma, Inc. Class A Common St (LIMN) cash flow conversion to assess how effectively this company generates cash.
Liminatus Pharma, Inc. Class A Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data. See net assets of Liminatus Pharma, Inc. Class A Common St for net asset value and shareholders' equity analysis.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Total Liabilities
The table below lists competitors of Liminatus Pharma, Inc. Class A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Helium Inc
V:HELI
|
Canada | CA$4.02 Million |
|
Roolife Group Ltd
AU:RLG
|
Australia | AU$1.09 Million |
|
Versus Systems Inc
NASDAQ:VS
|
USA | $3.46K |
|
Brera Holdings PLC Class B Ordinary Shares
NASDAQ:BREA
|
USA | $6.30 Million |
|
DXN Ltd
AU:DXN
|
Australia | AU$10.91 Million |
|
Golden State Mining Ltd
AU:GSM
|
Australia | AU$416.04K |
|
C&C Group plc
LSE:CCR
|
UK | GBX812.48 Million |
|
Wickes Group PLC
LSE:WIX
|
UK | GBX1.05 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Liminatus Pharma, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LIMN market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Liminatus Pharma, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Liminatus Pharma, Inc. Class A Common Stock (2021–2024)
The table below shows the annual total liabilities of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $18.70 Million | +23.06% |
| 2023-12-31 | $15.19 Million | +7.05% |
| 2022-12-31 | $14.19 Million | -34.20% |
| 2021-12-31 | $21.57 Million | -- |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 201… Read more